Bought when floated. Downhill all the way since then. Should I stay or should I go?

david,

In the absense of any additional information except your question, my only comment can be that the chart doesn't exactly inspire!

" alt="" />

232mill shares @ 88p equals about 2.04million market cap.
(this has dropped from 4.6million market cap at listing in Dec2004).

on par for another about 100k turnover, and about 250k operating losses for Jan-Jun 2005 period. Then the costs are supposed to stabilise (go down ???)

had 540k in cash earlier in the year - how much of it has been spent over past 6 months ??

seems like a sub-penny share.....

think that for the next 3 to 6 months, that the only way is down.
the only thing that may change it is if the turnover increases more than was forecast, for the Jan to Jun05 period.

i will be monitoring this one, but i wouldn't mind knowing what the biotech gurus think about PYC's product ???
if they think that most biotechs will buy it, then i would be waiting for the sp to bottom (where ? closer to .2 or .3p etcetc), otherwise would steer clear....

Andy & Belisce6

Thanks for taking the time and trouble to reply.

Hi David - As a matter of interest did you live in Singapore as a young boy ?

Hi Oakapples142 - Born in Cornwall near Redruth.

203 for 4.

OK it was another David Cornish. Seems you and I have been glued to channel 4 rather than this BB - Looking better. My daughter won an England one-day shirt in a raffle last night (signed by Kevin Pieterson - I was hoping he made a ton prior to her putting it on e-bay! - but you cannot play across the line too often and expect to get away with it )

304-7

Decided to stay with this one and although trading (mostly buys) has been very thin during the past five days the share price has virtually doubled during that period.

27 Jan + 0.05 + 6.90%
30 Jan + 0.13 + 16.13%

31 Jan + 0.13 + 13.89

1 Feb + 0.18 + 17.07% The chart kindly supplied by Andy confirms this and the results aren't due until March. Anyone else monitoring this one?

movement today up 22% - anyone still in this

Looks like a long forgotton thread..........news just out on this stock
NS Number : 0816A
Physiomics PLC
01 October 2009

?
Trading Update


Physiomics plc ("Physiomics" or "the Company")


Highlights:


* Revenue for year ended 30 June 2009 is expected to exceed the forecast of
GBP440k made in July 2008
* Good progress on Lilly collaboration, with license agreement signed in April
2009
* Achievement of second year milestone on Tempo project
* Looking to leverage Physiomics' technology for non-pharmaceutical application



Trading Update


Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is
pleased to update the market on its trading performance for the financial year
ended 30 June 2009. Revenues for the year were stronger than anticipated in a
previous trading statement issued on 28 July 2008 and we were able to build on
the improvement set out in the Interim statement issued in February 2009.


Conversion of debt into equity announced in August 2009 totalling GBP24k has
also helped to reduce the deficit in equity shareholders' funds which stood at
GBP102k at 31 December 2008.


Since the publication of its interim results for the period ended 31 December
2008, Physiomics has made good progress with its collaboration with Eli Lilly
and Company ("Lilly"), and in particular has announced on 2 April 2009 a license
agreement with Lilly for a customised version of its "ModelPlayer(TM)" for in
silico simulations of unspecified anticancer drugs. These are project specific
licences.


The Company is in discussion with a number of major players in the oncology
sector and expects to be able to say more in the near future.


Furthermore, Physiomics has announced on 23 June 2009 a successful
evaluation, by the European Commission, of the results from the second year of
the research program "TEMPO". This is the most important phase of the project
and Physiomics' partners will start imminently to verify in an in vivo
pre-clinical model the optimal chronotherapeutic schedules produced by
Physiomics. When validated, this will served as a base for a further grant
application, with the aim to test these chronotherapeutic schedules in a clinic
setting.


If the TEMPO approach is validated then it has both the potential to evaluate
existing oncology compounds to see whether a more efficient dosing regimen is
possible as well as helping formulate optimal study protocols for drugs used in
combination therapy. This would provide data on the ideal dosing sequence, time
interval between doses and amounts to be dosed.


The biological models are supported by sophisticated simulation software
environments developed by the team these include the Model Player(TM) and a
version of the proprietary SystemCell technology running on the IBM "Blue C"
super computer at the Institute of Life Sciences at Swansea University. We
intend to leverage this technology platform for non-pharmaceutical application
and we are looking at diversification in other areas and in particular Synthetic
Biology.


Commenting on the trading update, Physiomics' Chief Operating Officer, Dr
Christophe Chassagnole, said: "We are really pleased to have exceeded our
revenue forecast for the last year thanks to the good progress in our
collaborations. Based on these achievements plus the recent technical
development in the area of combination and scheduling and the potential to
branch out into wholly new applications, we are confident that we can stimulate
even greater interest in our technology."




For further information:

Waiting for contract news in 2 weeks.

Imissed it .

Managed to get a few after 12 at a good price.

I think these could be worth 5/6p in time.,

Overhang cleared and up she goes..

Its got a chance.

Broke 1p barrier this am .

what goes up ....... take profit whilst you can.